Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) CFO Robert E. Miller acquired 2,264 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The stock was purchased at an average price of $5.30 per share, for a total transaction of $11,999.20. Following the acquisition, the chief financial officer now directly owns 20,088 shares in the company, valued at approximately $106,466.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) traded down 3.00% during midday trading on Monday, hitting $5.17. The company had a trading volume of 15,638 shares. The stock has a 50 day moving average of $6.64 and a 200 day moving average of $6.83. The firm has a market cap of $22.27 million, a price-to-earnings ratio of 2.64 and a beta of 1.30. Sonoma Pharmaceuticals, Inc. has a 52-week low of $3.62 and a 52-week high of $8.25.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last issued its earnings results on Tuesday, August 8th. The company reported ($0.82) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.73) by $0.09. Sonoma Pharmaceuticals had a net margin of 54.36% and a negative return on equity of 44.24%. The firm had revenue of $3.84 million during the quarter. On average, analysts anticipate that Sonoma Pharmaceuticals, Inc. will post ($2.30) EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at

An institutional investor recently raised its position in Sonoma Pharmaceuticals stock. Janus Capital Management LLC boosted its position in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) by 41.1% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 37,926 shares of the company’s stock after buying an additional 11,053 shares during the period. Janus Capital Management LLC owned 0.89% of Sonoma Pharmaceuticals worth $272,000 as of its most recent SEC filing. 11.86% of the stock is currently owned by institutional investors.

Separately, Maxim Group set a $10.00 price objective on Sonoma Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 9th.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, formerly Oculus Innovative Sciences, Inc, is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid.

Insider Buying and Selling by Quarter for Sonoma Pharmaceuticals (NASDAQ:SNOA)

Receive News & Ratings for Sonoma Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.